{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:22:20Z","timestamp":1786648940779,"version":"build-2736575974"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.cca.2014.11.015","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T18:12:36Z","timestamp":1416507156000},"page":"143-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["ROMA, an algorithm for ovarian cancer"],"prefix":"10.1016","volume":"440","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-7968","authenticated-orcid":false,"given":"Anita Monika","family":"Chudecka-G\u0142az","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2014.11.015_bb0005","series-title":"Globocan 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No . 11","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.cca.2014.11.015_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE\u22125 a population based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0015","first-page":"934261","article-title":"Recent concepts of ovarian carcinogenesis: type I and type II","volume":"2014","author":"Koshiyana","year":"2014","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.cca.2014.11.015_bb0020","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0025","first-page":"408","article-title":"Comparison of different ovarian cancer detection algorithms","volume":"32","author":"Macuks","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0035","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0040","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s13277-012-0440-1","article-title":"An ovarian cancer malignancy risk index composed of HE4, CA 125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions","volume":"33","author":"Macus","year":"2012","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0045","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2013.01.018","article-title":"A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with adnexal mass","volume":"129","author":"Kaijser","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen CA 125 for ovarian cancer diagnosis","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cca.2014.11.015_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/uog.12551","article-title":"Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?","volume":"43","author":"Kaijser","year":"2014","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0060","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ygyno.2013.04.472","article-title":"Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumor s using biomarkers or the ROMA algorithm","volume":"130","author":"Kijser","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0065","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/1471-2407-13-423","article-title":"Symptoms, CA 125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses","volume":"13","author":"Pitta","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0070","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","article-title":"Comparison of serum human epididymis protein 4 with cancer antigen 125 as tumor marker in patients with malignant and non-malignant disease","volume":"57","author":"Escudero","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2014.11.015_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","article-title":"Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence","volume":"110","author":"Havrilesky","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0080","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2008.19.2484","article-title":"Development of a multimarker assay for early detection of ovarian cancer","volume":"28","author":"Yurkovetsky","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.6061\/clinics\/2012(05)06","article-title":"A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses","volume":"67","author":"Anton","year":"2012","journal-title":"Clinics"},{"key":"10.1016\/j.cca.2014.11.015_bb0090","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ygyno.2013.06.029","article-title":"Risk and benefits of screening women for ovarian cancer: a systematic review and meta-analysis","volume":"130","author":"Reade","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0095","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ejca.2011.12.003","article-title":"Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses","volume":"48","author":"Van Gorp","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0100","doi-asserted-by":"crossref","first-page":"475983","DOI":"10.1155\/2011\/475983","article-title":"Potential markers for detection and monitoring of ovarian cancer","volume":"2011","author":"Rein","year":"2011","journal-title":"J Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/978-3-540-37696-5_9","article-title":"Prevention and early detection of ovarian cancer: mission impossible?","volume":"174","author":"Bast","year":"2007","journal-title":"Recent Results Cancer Res"},{"issue":"Suppl.","key":"10.1016\/j.cca.2014.11.015_bb0110","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/IGC.0b013e318251c97d","article-title":"Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers","volume":"22","author":"Bast","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2217\/bmm.12.70","article-title":"From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade","volume":"6","author":"Leung","year":"2012","journal-title":"Biomark Med"},{"key":"10.1016\/j.cca.2014.11.015_bb0120","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1515\/cclm-2012-0373","article-title":"HE4 in gynecological cancers: report of a European investigators and experts","volume":"50","author":"Plebani","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.11.015_bb0125","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1515\/CCLM.2011.073","article-title":"ROMA or death: advances in epithelial ovarian cancer diagnosis","volume":"49","author":"Plebani","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.11.015_bb0130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-0528.1999.tb08318.x","article-title":"Comparison of two malignancy risk indices based on serum Ca125, ultrasound score and menopausal status in the diagnosis of ovarian masses","volume":"106","author":"Morgante","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0135","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00006250-199903000-00028","article-title":"The risk of malignancy index to evaluate potential ovarian cancers in local hospitals","volume":"93","author":"Tinglustad","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0140","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1158\/1055-9965.EPI-10-0580","article-title":"The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers","volume":"19","author":"Zhang","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cca.2014.11.015_bb0145","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1097\/AOG.0b013e31821b1d80","article-title":"Performance of the American Collage of Obstetricians and Gynecologists' ovarian tumor referral guidelines with multivariate index assay","volume":"117","author":"Ware Miller","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0150","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/AOG.0b013e31821b5118","article-title":"Effectiveness of multivariate index assay in the preoperative assessment of ovarian tumors","volume":"117","author":"Ueland","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0155","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cca.2014.11.015_bb0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2014.11.015_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0090-8258(90)90394-Z","article-title":"Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease","volume":"39","author":"Tholander","year":"1990","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0170","first-page":"145","article-title":"CA 125 seric levels in non-malignant pathologies","volume":"71","author":"Ruibal","year":"1984","journal-title":"Bull Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0175","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0002-9378(84)90444-7","article-title":"Elevation of serum CA 25 in carcinomas of fallopian tube, endometrium, and endocervix","volume":"148","author":"Niloff","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","article-title":"The CA 125 tumor-associated antigen: a review of the literature","volume":"4","author":"Jacobs","year":"1989","journal-title":"Hum Reprod"},{"key":"10.1016\/j.cca.2014.11.015_bb0185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1148\/radiol.11090563","article-title":"Early diagnosis of ovarian carcinoma: is a solution in sight?","volume":"259","author":"Lutz","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.cca.2014.11.015_bb0190","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA 125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0195","doi-asserted-by":"crossref","first-page":"200s","DOI":"10.1200\/JCO.2003.01.068","article-title":"Status of tumor markers in ovarian cancer screening","volume":"21","author":"Bast","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incoroporatingg RECIST 1.1 and CA 125 agreed by the Gynecologic Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000217748","article-title":"Use of serum tumor markers in the differentia diagnosis between ovarian and colorectal carcinomas","volume":"13","author":"Yedema","year":"1992","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0210","first-page":"A4331","article-title":"Combination of cancer antigen CA125 and carcinoembryonic antigen can improve ovarian cancer diagnosis","volume":"58","author":"Sorensen","year":"2011","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.cca.2014.11.015_bb0215","first-page":"1002","article-title":"Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis","volume":"79","author":"Makar","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0220","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1471-0528.1994.tb13550.x","article-title":"Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer","volume":"101","author":"Parker","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0225","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-11-0635","article-title":"Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian management","volume":"20","author":"Bandiera","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cca.2014.11.015_bb0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1757-2215-6-45","article-title":"The plasma concentration of VEGF, HE4 and CA 125 as new biomarkers panel in different stages and subtypes of epithelial ovarian tumors","volume":"6","author":"\u0141awicki","year":"2013","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0235","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstr\u00f6m","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0240","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1517\/17530059.2011.559459","article-title":"Two novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma","volume":"5","author":"Hellstrom","year":"2011","journal-title":"Exp Opin Med Diagn"},{"key":"10.1016\/j.cca.2014.11.015_bb0245","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0250","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0b013e318234f852","article-title":"The utility of human epididymal protein 4, cancer antigen 125, and risk form malignancy algorithm in ovarian cancer and endometriosis","volume":"22","author":"Kadija","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0255","first-page":"605","article-title":"HE4- a novel promising serum marker in the diagnosis of ovarian carcinoma","volume":"32","author":"Langm\u00e1r","year":"2011","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0260","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1095\/biolreprod45.2.350","article-title":"A major human epididymis \u2014 specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors","volume":"45","author":"Kirchoff","year":"1991","journal-title":"Biol Reprod"},{"key":"10.1016\/j.cca.2014.11.015_bb0265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1530\/ror.0.0030086","article-title":"Molecular characterization of epididymal proteins","volume":"3","author":"Kirchoff","year":"1998","journal-title":"Rev Reprod"},{"key":"10.1016\/j.cca.2014.11.015_bb0270","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.bbrc.2012.02.008","article-title":"Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility","volume":"419","author":"Lu","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cca.2014.11.015_bb0275","first-page":"3133","article-title":"Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer","volume":"124","author":"Zou","year":"2011","journal-title":"Chin Med J"},{"key":"10.1016\/j.cca.2014.11.015_bb0280","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-7-61","article-title":"WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung","author":"Bingle","year":"2006","journal-title":"Respir Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0285","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","article-title":"The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms","volume":"21","author":"Bingle","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.cca.2014.11.015_bb0290","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cca.2014.11.015_bb0295","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-1119(99)00035-9","article-title":"Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray","volume":"229","author":"Wang","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.cca.2014.11.015_bb0300","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0378-1119(99)00342-X","article-title":"Comparative hybridization of an array of 21500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas","volume":"238","author":"Schummer","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.cca.2014.11.015_bb0305","first-page":"6281","article-title":"Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer","volume":"60","author":"Hough","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0310","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumors","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cca.2014.11.015_bb0315","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/73432","article-title":"Systematic variation in gene expression patterns in human cancer cell lines","volume":"24","author":"Ross","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.cca.2014.11.015_bb0320","first-page":"251","article-title":"Human epididymis protein 4 reference limits and natural variations in a Nordic reference population","volume":"44","author":"Bolstad","year":"2008","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0325","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","article-title":"The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?","volume":"49","author":"Montagnana","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.11.015_bb0330","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0335","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.ajog.2011.12.029","article-title":"Serum HE4 levels are less frequently elevated than CA 125 in women with benign gynecological disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0340","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/IGC.0b013e318263efa2","article-title":"Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma","volume":"22","author":"Wu","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0345","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1007\/s13277-014-1811-6","article-title":"Diagnostic accuracy of serum HE4, CA 125 and ROMA in patients with ovarian cancer: a meta analysis","volume":"35","author":"Wang","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0350","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.7314\/APJCP.2012.13.11.5427","article-title":"Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis","volume":"13","author":"Lin","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.cca.2014.11.015_bb0355","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","article-title":"Human epididymis protein 4 for differential diagnosis between benign gynaecologic disease and ovarian cancer: a systematic review and meta-analysis","volume":"167","author":"Lin","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0360","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-0-387-68969-2_2","article-title":"SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA 125 and\/or each other","volume":"622","author":"Hellstrom","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0365","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"Holomb","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0370","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ygyno.2012.03.011","article-title":"Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women","volume":"125","author":"Hallamaa","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0375","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1757-2215-6-44","article-title":"The use of HE4, CA 125 and CA 72\u20134 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer","volume":"6","author":"Anastasi","year":"2013","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0380","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/IGC.0b013e318249bee7","article-title":"Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign disease","volume":"22","author":"Zheng","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0385","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant tumours from ovarian endometriotic cysts","volume":"100","author":"Huhinten","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0390","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00432-013-1435-z","article-title":"Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta analysis of published studies","volume":"139","author":"Xu","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0395","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/IGC.0b013e3182681cfd","article-title":"The prognostic and predictive value of combined HE4 and CA125 in ovarian cancer patients","volume":"22","author":"Steffensen","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0400","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1245\/s10434-011-1943-5","article-title":"Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer","volume":"19","author":"Kong","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0410","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7314\/APJCP.2014.15.1.101","article-title":"HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer","volume":"15","author":"Chen","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.cca.2014.11.015_bb0415","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/IGC.0b013e3182225509","article-title":"Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer","volume":"21","author":"Hynninen","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0420","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ygyno.2012.11.023","article-title":"Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients. Results from the OVCAD study","volume":"128","author":"Braicu","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0425","first-page":"382","article-title":"Human epididymal protein 4 (HE4) is a novel biomarker and promising prognostic factor in ovarian cancer patients","volume":"33","author":"Chudecka-G\u0142az","year":"2012","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0430","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1757-2215-7-62","article-title":"Serum HE4, CA125, YKL-10, bcl-2, cathepsin-l and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer","volume":"7","author":"Chudecka-G\u0142az","year":"2014","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0435","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?","volume":"128","author":"Angioli","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0440","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0445","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0450","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/IGC.0b013e31821bb88c","article-title":"Considering early detection of relapsed ovarian cancer : a review of the literature","volume":"21","author":"Geurts","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0455","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","article-title":"Diagnostic performance of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases","volume":"44","author":"Park","year":"2011","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cca.2014.11.015_bb0460","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1515\/CCLM.2011.085","article-title":"Evaluation of accuracy of serum human epididymis protein 4 in combination with CA 125 for detecting ovarian cancer : a prospective case control study in Korean population","volume":"49","author":"Kim","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.11.015_bb0465","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00404-013-2722-2","article-title":"Evaluation of HE4 as an extra biomarker to CA 125 to improve detection of ovarian carcinoma: is it time for step forward","volume":"288","author":"Azzam","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.cca.2014.11.015_bb0470","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","article-title":"Use of a symptom index, CA 125 and HE4 to predict ovarian cancer","volume":"116","author":"Andersen","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.cca.2014.11.015_bb0475","doi-asserted-by":"crossref","first-page":"e29533","DOI":"10.1371\/journal.pone.0029533","article-title":"Comprehensiveserum profiling for the discovery of epithelial ovarian cancer biomarkers","volume":"6","author":"Yip","year":"2011","journal-title":"PLos ONE"},{"key":"10.1016\/j.cca.2014.11.015_bb0480","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.3390\/ijms14036026","article-title":"HE4 (WFDC2) promotes tumour growth in endometrial cancer cell lines","volume":"14","author":"Li","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cca.2014.11.015_bb0485","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0490","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cca.2012.10.058","article-title":"Detection and monitoring of ovarian cancer","volume":"415","author":"Su","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.11.015_bb0495","unstructured":"ROMA\u2122 (HE4EIA + ARCHITECT CA125II\u2122) Prod. No. 404-10US. Instructions for use. 2011\u201309."},{"key":"10.1016\/j.cca.2014.11.015_bb0500","series-title":"Roche multicentre evaluation study","article-title":"Elecsys\u00ae HE4 and CA 125 II and their use in the risk assessment of epithelial ovarian cancer by ROMA (Risk of Ovarian Malignancy)","year":"2011"},{"key":"10.1016\/j.cca.2014.11.015_bb0505","series-title":"Two strong pillars in the management of ovarian cancer ARCHITECT HE4+CA125","year":"2014"},{"key":"10.1016\/j.cca.2014.11.015_bb0510","unstructured":"HE4 EIA Prod. No. 404\u201310. Instructions for use. 2014\u201304."},{"key":"10.1016\/j.cca.2014.11.015_bb0515","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2012.09.034","article-title":"The use of HE4 in the prediction of ovarian cancer in Asian women with pelvic mass","volume":"128","author":"Chan","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0520","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1007\/s13277-014-1945-6","article-title":"HE4, CA 125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer","volume":"35","author":"Ortiz-Munoz","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0525","first-page":"2081","article-title":"The diagnostic accuracy of two epididymis protein 4 (HE4) testing system in combination with CA 125 in the differential diagnosis of ovarian masses","volume":"49","author":"Lenhardt","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.11.015_bb0530","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1757-2215-5-20","article-title":"High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer","volume":"5","author":"Kalapotharakos","year":"2012","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.cca.2014.11.015_bb0535","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cca.2011.04.028","article-title":"HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm","volume":"412","author":"Ruggieri","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.11.015_bb0540","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.clinbiochem.2013.08.019","article-title":"The reference intervals for HE4, CA 125, and ROMA in healthy female with electrochemiluminescence immunoassay","volume":"46","author":"Yang","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cca.2014.11.015_bb0545","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA 125 as diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cca.2014.11.015_bb0550","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3892\/ol.2012.757","article-title":"HE4 protein and SMRP: potential novel biomarkers in ovarian cancer detection","volume":"4","author":"Fritz-Rdzanek","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.cca.2014.11.015_bb0555","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1158\/1055-9965.EPI-12-0646","article-title":"Biomarkers for screening, diagnosis and monitoring ovarian cancer","volume":"21","author":"Kobayashi","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.cca.2014.11.015_bb0560","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/uog.12323","article-title":"Improving strategies for diagnosisng ovarian cancer: a summary of the international ovarian tumor analysis (IOTA) studies","volume":"41","author":"Kaijser","year":"2013","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.cca.2014.11.015_bb0565","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1600-0412.2012.01359.x","article-title":"DANISH PELVIC MASS OVARIAN CANCER STUDY. Risk of malignancy index used as diagnostic tool in a tertiary centre for patients with pelvic mass","volume":"91","author":"Hakansson","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.cca.2014.11.015_bb0570","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA 125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0575","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3802\/jgo.2011.22.4.244","article-title":"Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass","volume":"22","author":"Partheen","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0580","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","article-title":"Her novel tumor marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases","volume":"32","author":"Molina","year":"2011","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0585","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ygyno.2012.11.026","article-title":"Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome","volume":"128","author":"Sandri","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0590","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA 125, risk of malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass","volume":"127","author":"Karlsen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0595","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1471-0528.2012.03297.x","article-title":"Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol","volume":"119","author":"Van Calster","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.cca.2014.11.015_bb0600","first-page":"4137","article-title":"HE4 and ROMA index in Czech postmenopausal women","volume":"32","author":"Novotny","year":"2012","journal-title":"Anticancer Res"},{"issue":"Supplement 6","key":"10.1016\/j.cca.2014.11.015_bb0605","first-page":"vi24","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up","volume":"24","author":"Ledermann","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl.","key":"10.1016\/j.cca.2014.11.015_bb0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2009.27.18_suppl.1","article-title":"A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05\/EORTC 55955 trials)","volume":"27","author":"Rustin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cca.2014.11.015_bb0620","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s13277-012-0381-8","article-title":"Role of HE4, CA 72.4 and CA 125 in monitorin ovarian cancer","volume":"33","author":"Granato","year":"2012","journal-title":"Tumor Biol"},{"key":"10.1016\/j.cca.2014.11.015_bb0625","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumor Biol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114005208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114005208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T12:41:49Z","timestamp":1566045709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898114005208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":123,"alternative-id":["S0009898114005208"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2014.11.015","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ROMA, an algorithm for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2014.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}